Immuneering Corp financial data

Symbol
IMRX on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 06 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1463% % 66%
Debt-to-equity 9% % -48%
Return On Equity -43% % 57%
Return On Assets -40% % 53%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $101,100,000 USD 166%
Weighted Average Number of Shares Outstanding, Basic 44,011,830 shares 47%
Weighted Average Number of Shares Outstanding, Diluted 44,011,830 shares 47%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $42,048,461 USD -12%
General and Administrative Expense $17,298,241 USD 7.6%
Operating Income (Loss) $59,375,969 USD 7.3%
Net Income (Loss) Attributable to Parent $56,024,898 USD 8.2%
Earnings Per Share, Basic -1.27 USD/shares 38%
Earnings Per Share, Diluted -1.27 USD/shares 38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $128,645,025 USD 256%
Assets, Current $176,245,954 USD 345%
Property, Plant and Equipment, Net $938,481 USD -16%
Operating Lease, Right-of-Use Asset $3,322,249 USD -9.4%
Goodwill $6,690,431 USD 0%
Other Assets, Noncurrent $283,562 USD -78%
Assets $231,985,010 USD 340%
Accounts Payable, Current $1,542,737 USD -21%
Accrued Liabilities, Current $7,842,367 USD 58%
Liabilities, Current $10,073,721 USD 34%
Operating Lease, Liability, Noncurrent $3,427,321 USD -10%
Liabilities $13,501,042 USD 19%
Accumulated Other Comprehensive Income (Loss), Net of Tax $81,332 USD
Retained Earnings (Accumulated Deficit) $280,320,084 USD -25%
Stockholders' Equity Attributable to Parent $218,483,968 USD 428%
Liabilities and Equity $231,985,010 USD 340%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,080,638 USD 9.1%
Net Cash Provided by (Used in) Financing Activities $13,810,559 USD 1309%
Net Cash Provided by (Used in) Investing Activities $21,392,522 USD 13%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $279,024 USD -104%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $128,645,025 USD 256%
Deferred Tax Assets, Valuation Allowance $73,378,421 USD 24%
Deferred Tax Assets, Gross $73,691,947 USD 24%
Operating Lease, Liability $3,824,425 USD -8.1%
Depreciation $90,209 USD 18%
Payments to Acquire Property, Plant, and Equipment $8,945 USD -76%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $55,943,566 USD 8.3%
Lessee, Operating Lease, Liability, to be Paid $5,229,123 USD -12%
Property, Plant and Equipment, Gross $2,341,056 USD 6.2%
Operating Lease, Liability, Current $397,104 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year Two $784,737 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $761,877 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,404,698 USD -22%
Lessee, Operating Lease, Liability, to be Paid, Year Three $808,278 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $40,134,991 USD 59%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $1,493,736 USD 31%
Lessee, Operating Lease, Liability, to be Paid, Year Four $832,527 USD 3%
Operating Lease, Payments $183,546 USD -4.7%
Additional Paid in Capital $498,658,072 USD 88%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $29,267 USD 0%
Depreciation, Depletion and Amortization $324,517 USD -8.8%
Deferred Tax Assets, Net of Valuation Allowance $313,526 USD -9%
Share-based Payment Arrangement, Expense $6,311,135 USD -2.9%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%